Boston Scientific Corporation [BSX] Revenue clocked in at $11.47 billion, up 1.51% YTD: What’s Next?


Boston Scientific Corporation [NYSE: BSX] gained 1.51% on the last trading session, reaching $43.12 price per share at the time. The company report on December 28, 2021 that Saken Khokhar to Lead Diversity Alliance for Science.

Northampton, MA –News Direct– Boston Scientific.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Growing up in South Africa during apartheid, Saken Khokhar witnessed the devastating effects of discrimination and segregation, experiences that instilled in her a desire to build more diverse and inclusive societies. Since 2017, as the supplier diversity manager for Boston Scientific, Saken has increased the company’s partnerships with small and diverse businesses by more than 200% and has led the company to spend approximately $1.9 billion on the services of diverse suppliers. In 2020 alone, under Saken’s leadership, Boston Scientific spent $599 million on diverse suppliers.

Boston Scientific Corporation represents 1.42 billion in outstanding shares, while the company has a total market value of $60.64 billion with the latest information. BSX stock price has been found in the range of $42.10 to $43.15.

If compared to the average trading volume of 7.52M shares, BSX reached a trading volume of 5069905 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Boston Scientific Corporation [BSX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BSX shares is $51.09 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BSX stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

RBC Capital Mkts have made an estimate for Boston Scientific Corporation shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on December 10, 2021. The new note on the price target was released on May 26, 2021, representing the official price target for Boston Scientific Corporation stock. Previously, the target price had yet another raise to $51, while Barclays analysts kept a Overweight rating on BSX stock.

The Average True Range (ATR) for Boston Scientific Corporation is set at 0.99, with the Price to Sales ratio for BSX stock in the period of the last 12 months amounting to 5.29. The Price to Book ratio for the last quarter was 3.73, with the Price to Cash per share for the same quarter was set at 1.38. Price to Free Cash Flow for BSX in the course of the last twelve months was 37.48 with Quick ratio for the last quarter at 1.20.

Trading performance analysis for BSX stock

Boston Scientific Corporation [BSX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by 0.00. With this latest performance, BSX shares gained by 8.89% in over the last four-week period, additionally sinking by -1.15% over the last 6 months – not to mention a rise of 22.26% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BSX stock in for the last two-week period is set at 59.76, with the RSI for the last a single of trading hit 63.15, and the three-weeks RSI is set at 56.72 for Boston Scientific Corporation [BSX]. The present Moving Average for the last 50 days of trading for this stock 41.71, while it was recorded at 43.00 for the last single week of trading, and 42.60 for the last 200 days.

Boston Scientific Corporation [BSX]: A deeper dive into fundamental analysis

Boston Scientific Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.50.

Boston Scientific Corporation [BSX]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BSX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Boston Scientific Corporation go to 23.00%.

>> 7 Top Picks for the Post-Pandemic Economy <<

An analysis of insider ownership at Boston Scientific Corporation [BSX]

There are presently around $54,994 million, or 94.30% of BSX stock, in the hands of institutional investors. The top three institutional holders of BSX stocks are: BLACKROCK INC. with ownership of 122,400,261, which is approximately 3.868% of the company’s market cap and around 0.20% of the total institutional ownership; VANGUARD GROUP INC, holding 111,212,803 shares of the stock with an approximate value of $4.72 billion in BSX stocks shares; and FMR LLC, currently with $4.57 billion in BSX stock with ownership of nearly 4.156% of the company’s market capitalization.

414 institutional holders increased their position in Boston Scientific Corporation [NYSE:BSX] by around 67,835,949 shares. Additionally, 345 investors decreased positions by around 52,624,495 shares, while 162 investors held positions by with 1,174,121,768 shares. The mentioned changes placed institutional holdings at 1,294,582,212 shares, according to the latest SEC report filing. BSX stock had 78 new institutional investments in for a total of 13,451,249 shares, while 62 institutional investors sold positions of 5,367,975 shares during the same period.